Article Per Year (5 Year)
p-Index From 2019 - 2024
0.408
P-Index
This Author published in this journals
All Journal IJRETINA - International Journal of Retina Ophthalmologica Indonesiana
A.K. Ansyori
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Management Of Eales’ Disease Grade III B: A Rare Case Agung Putra Evasha; Ramzi Amin; A.K. Ansyori
International Journal of Retina Vol 6 No 2 (2023): International Journal of Retina (IJRetina) - INAVRS
Publisher : Indonesian Vitreoretinal Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35479/ijretina.2023.vol006.iss002.248

Abstract

Introduction: Eales' disease is an idiopathic, bilateral, occlusive retinal vasculopathy that primarily affects young, predominately male patients. It seems to have multiple causes and is probably immunologic in nature. Recurrent vitreous hemorrhages, macular degeneration, and tractional or mixed retinal detachments involving the macula can all cause some patients to experience severe vision loss. Case Report: A 39-year-old male with vitreous hemorrhage caused by Eales Disease grade III Bwith an initial visual acuity 1/300 came to our department. Ultrasound imaging showed themembrane like lesion with 1/2 retinal reflectivity, after moderate movement and vitreoushemorrhage on both eyes. The photo-fundus showed there is decreased fovea reflex andperimacular exudate with visible contours of sclerotic blood vessels, visible cotton wall spot, andmacroaneurysm. There is also haze grade 3 on media, visible folds in the inferior part, visibleshadows of cotton wall spots. The patient underwent pars plana vitrectomy with endolaser tomanage the disease. Discussion: In this case, patient was diagnosed as vitreous hemorrhage caused by Eales Diseasegrade III B on both eyes but it getting worse on left eye further. We chose to perform PPV withendolaser on right eye. Based on improved visual acuity and less hemorrhage, the right eye'soutcome was favorable, while the left eye, which was not treated, had a worsening of thesituation. Only eyes with a non-resolving vitreous hemorrhage after three months should have avitrectomy.Conclusion: The treatment of this patient's case produced good anatomical and functionaloutcomes for the right eye, but the left eye, unfortunately, has a major issue. In order to furtherconfirm the results, longer follow-up is still required.
Anti-RAGE (Receptor Advanced Glycation End products) Antibody Improves Diabetic Retinopathy in Rats via Hypoglycemic and Anti-inflammatory Mechanism Tiara Bunga Indiarsih; Ramzi Amin; A.K. Ansyori
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/xny05743

Abstract

Background: Receptor advanced glycation end products (RAGE) activation plays an essential role in diabetic retinopathy (DR) progression. This study was aimed to explore the role of anti-RAGE antibodies (RAGE antagonists) in inhibiting DR progression through their hypoglycemic and anti- inflammatory mechanism in diabetic retinopathy induced rats. Methods: A total of 30 male Wistar rats were randomly divided into five group. The group was consisted of normal control group, DR group without treatment, DR group with anti-RAGE 1 g/kg BW, 10 g/kg BW, and 100 g/kg BW. To assess the diabetic retinopathy, fundus photographs were taken every week using a camera with 16x magnification placed in front of the rat's eyes. Blood glucose was checked by the glucose oxidase-peroxidase method. Retinal TNF-? levels and VEGF were examined using an enzyme-linked immunosorbent assay (ELISA) kit. Results: The finding of this study showed that anti-RAGE treatment at dose of 10 and 100 g/kg BW, HbA1c levels were significantly higher (p< 0.05) compared to the normal control group but significantly lower (p< 0.05) than in the diabetes group. The mean blood vessel diameter in the DR+anti-RAGE 10 and 100 g/kg BW groups was significantly lower than in the diabetic retinopathy group (p< 0.05). The administration of anti-RAGE 10 and 100 g/kg BW showed the ability to significantly reduce VEGF levels compared to the DR group (p< 0.05). Conclusions: This study revealed at doses of 10 and 100 g/kg BW, anti-RAGE antibodies improved diabetic retinopathy in Wistar rats through hypoglycemic effects and anti-inflammatory mechanisms.
Co-Authors Agung Putra Evasha Ramzi Amin, Ramzi Tiara Bunga Indiarsih